Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07527221 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 40 → 64 participants
    • Trial arms changed: 5 → 8
    • Secondary endpoints: 9 to 14
    • Study description expanded, about 159 words
    v3
  2. Recruitment opened
    • Start date changed from estimate of Apr 30, 2026 to Apr 16, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in healthy adult volunteers.
Trial Details
NCT Number NCT07527221
Lead Sponsor Eilean Therapeutics AU Pty Ltd
Conditions
(from sponsor)		 Healthy Volunteers
Related terms Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Polycythemia, Primary Myelofibrosis, Thrombocythemia, Essential
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov